SCHEMBL771570

SCHEMBL771570

CN1CCN(C(=O)C(=O)N2CCC3CCCC=C3C2)CC1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTT P42858 1/20 0.35
CHRM3 P20309 4/20 0.35
POLB P06746 3/20 0.34
LMNA P02545 2/20 0.34
KMT2A Q03164 1/20 0.34
TLR9 Q9NR96 1/20 0.34
TLR8 Q9NR97 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
ALDH1A1 P00352 1/20 0.33
RAD52 P43351 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HPGD P15428 3/20 0.33
MAPT P10636 1/20 0.33
CHRM1 P11229 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP1A2 P05177 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772492 0.90 L3MBTL3 (0.33) L3MBTL3L3MBTL1POLBALDH1A1SMN1; SMN2
SCHEMBL770485 0.87 ACHE (0.38) POLBLMNAKMT2AALDH1A1SMN1; SMN2
SCHEMBL770905 0.87 ALDH1A1 (0.36) L3MBTL3L3MBTL1LMNAKMT2AALDH1A1
SCHEMBL770894 0.85 KDM1A (0.39) L3MBTL3L3MBTL1HTTLMNAKMT2A
SCHEMBL770448 0.85 SMN1; SMN2 (0.44) L3MBTL3L3MBTL1HTTCHRM3LMNA
SCHEMBL770413 0.84 RBP4 (0.38) L3MBTL3L3MBTL1POLBLMNAALDH1A1
SCHEMBL771078 0.83 NPC1 (0.42) HTTLMNAKMT2AALDH1A1RAD52
SCHEMBL769878 0.81 KMT2A (0.36) POLBKMT2AALDH1A1SMN1; SMN2HPGD
SCHEMBL15378283 0.81 KCNH2 (0.34) L3MBTL3L3MBTL1POLBALDH1A1SMN1; SMN2
SCHEMBL772030 0.80 TSHR (0.52) HTTKMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 L3MBTL3 4809/4885L3MBTL1 4097/4885HTT 412/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 L3MBTL3 4809/4885L3MBTL1 4090/4885HTT 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.